Videos
Live Endoscopy – 9 Sessions
A highlight at the Symposium 236 in Copenhagen was live endoscopy transmission from the University Hospital Augsburg (Germany) and Karolinska Hospital (Stockholm Sweden) with special cases in GI neoplasia demonstrated by experts in these fields.
Session 1: Endoscopic ultrasound evaluation and biliary drainage with endoscopic retrograde cholangiopancreatography or endoscopic ultrasound evaluation
16:27 min, Endoscopist: Alexander Waldthaler (Stockholm, Sweden)
Session 2: Endoscopic retrograde cholangiopancreatography with cholangioscopy for new biopsies and extraction of stones and plastic stents
8:17 min, Endoscopist: Niklas Fagerström (Stockholm, Sweden)
Session 3: Diagnosis and endoscopic treatment of early Barrett's neoplasia (including AI)
52:47 min, Endoscopist: Andreas Probst (Augsburg, Germany)
Session 4: Diagnosis and endoscopic resection
8:51 min, Endoscopist: Sandra Nagl (Augsburg, Germany)
Session 5: Endoscopic full thickness resection of the resection site
15:45 min, Endoscopist: Karel Caca (Ludwigsburg, Germany)
Session 6: Cholangioscopy via EDGE: intraductal papillary mucinous neoplasm of the bile duct?
8:01 min, Endoscopist: Frederik Swahn (Stockholm, Sweden)
Session 7: Endoscopic ultrasound (EUS)-guided hepaticogastrostomy
21:16 min, Endoscopist: Alexander Waldthaler (Stockholm, Sweden)
Session 8: Diagnosis and endoscopic treatment of colorectal neoplasia
7:48 min, Endoscopist: Andreas Probst (Augsburg, Germany)
Session 9: Diagnosis and endoscopic resection
11:31 min, Endoscopist: Sandra Nagl (Augsburg, Germany)
Live Endoscopy – Learning from the Experts, Symposium 236 "Endoscopy in GI-Oncology: Standards and Innovations", March 15 – 16, 2024 in Copenhagen.
©Falk Foundation e.V., Freiburg. All rights reserved.
Vermeire S, J Crohns Colitis. 2024;18(4):540–7
Early vs. late use of vedolizumab in ulcerative colitis: No significant differences in clinical, endoscopic and histological outcomes following vedolizumab therapy were observed in this prospective trial between “early” and “late” disease stages.
Bokemeyer B, Aliment Pharmacol Ther. 2024;59(9):1082–95
Impact of IBD nurse specialist care on patient quality of life (QoL) in Germany: Additional care with IBD nurse specialists in patients with inflammatory bowel diseases receiving biologic therapies did not result in significant differences in disease-associated QoL in the IBDBIO-ASSIST trial. However, patients with impaired QoL at study entry experienced significant benefits from additional care provided by IBD nurse specialists.
Nardelli S, J Hepatol. 2024;80(4):596–602
Mortality in hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS): HE is a major complication after implantation of a TIPS. However, a recent large cohort study demonstrates that episodic overt HE does not increase mortality.
Kjaergaard M, Clin Gastroenterol Hepatol. 2024;22(5):1037–47.e9
Liver fibrosis screening and lifestyle modification: A recent prospective study indicates that fibrosis screening in at-risk patients is associated with sustained improvements in alcohol consumption, diet, weight and exercise. The changes are most pronounced in screening positive participants (evidence of fibrosis), but are not limited to this group.
Girardi P, Dig Liver Dis. 2024;56(5):810–7
Prognostic value of procalcitonin in liver cirrhosis and infection: A current study examined the prognostic significance of various infection parameters in patients with or without liver cirrhosis. In patients with liver cirrhosis and acute infection, in addition to the leukocyte count and lactate, procalcitonin at admission was a good prognostic indicator for the course of hospitalization.
Kwan MC, Gut. 2024;73(4):629–38
Cyst fluid carcinoembryonic antigen (CEA) as diagnostic marker for pancreatic mucinous cysts: Cyst fluid CEA continues to be a useful test in the diagnosis of mucinous pancreatic cysts, but appears to be less specific as previously reported. Raising the CEA threshold to 250 ng/ml may be considered to maintain specificity for differentiating mucinous from non-mucinous cysts.
Symposium 237
XXVII International Bile Acid Meeting: Bile Acids in Health and Disease 2024
July 5 – 6, 2024, Edinburgh, Great Britain
Edinburgh International Conference Centre (EICC), The Exchange, Edinburgh EH3 8EE, Great Britain
Symposium 238
Inflammatory Diseases of the GI Tract: Where Do We Stand?
November 8 – 9, 2024, Florence, Italy
Palazzo die Congressi, Piazza Adua 1, 50123 Florence, Italy